OA16449A - New form of administration of enkephalinase inhibitor. - Google Patents
New form of administration of enkephalinase inhibitor. Download PDFInfo
- Publication number
- OA16449A OA16449A OA1201300239 OA16449A OA 16449 A OA16449 A OA 16449A OA 1201300239 OA1201300239 OA 1201300239 OA 16449 A OA16449 A OA 16449A
- Authority
- OA
- OAPI
- Prior art keywords
- aqueous suspension
- anyone
- suspension according
- agent
- preceding daims
- Prior art date
Links
- 239000002792 enkephalinase inhibitor Substances 0.000 title claims abstract description 23
- ODUOJXZPIYUATO-UHFFFAOYSA-N Racecadotril Chemical compound C=1C=CC=CC=1COC(=O)CNC(=O)C(CSC(=O)C)CC1=CC=CC=C1 ODUOJXZPIYUATO-UHFFFAOYSA-N 0.000 claims abstract description 37
- 229960002281 racecadotril Drugs 0.000 claims abstract description 37
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 10
- 201000008286 diarrhea Diseases 0.000 claims abstract description 8
- 229950008996 Dexecadotril Drugs 0.000 claims abstract description 7
- ODUOJXZPIYUATO-IBGZPJMESA-N benzyl 2-[[(2R)-2-(acetylsulfanylmethyl)-3-phenylpropanoyl]amino]acetate Chemical compound C([C@@H](CSC(=O)C)C(=O)NCC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 ODUOJXZPIYUATO-IBGZPJMESA-N 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 7
- 239000007900 aqueous suspension Substances 0.000 claims description 51
- 239000000725 suspension Substances 0.000 claims description 41
- 229960005343 Ondansetron Drugs 0.000 claims description 21
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 claims description 18
- 239000006172 buffering agent Substances 0.000 claims description 14
- 239000000375 suspending agent Substances 0.000 claims description 13
- 239000002562 thickening agent Substances 0.000 claims description 13
- 230000002335 preservative Effects 0.000 claims description 12
- 239000003755 preservative agent Substances 0.000 claims description 12
- 235000010234 sodium benzoate Nutrition 0.000 claims description 9
- 239000004299 sodium benzoate Substances 0.000 claims description 9
- 239000003765 sweetening agent Substances 0.000 claims description 9
- 229920001285 xanthan gum Polymers 0.000 claims description 9
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 8
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 8
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 8
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims description 8
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 235000003599 food sweetener Nutrition 0.000 claims description 7
- 239000001509 sodium citrate Substances 0.000 claims description 7
- 239000011778 trisodium citrate Substances 0.000 claims description 7
- 239000000230 xanthan gum Substances 0.000 claims description 7
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 6
- -1 isostearyl alcohols Chemical class 0.000 claims description 6
- 235000010493 xanthan gum Nutrition 0.000 claims description 6
- 229940082509 xanthan gum Drugs 0.000 claims description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 208000005577 Gastroenteritis Diseases 0.000 claims description 3
- 229940075582 Sorbic Acid Drugs 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 235000010980 cellulose Nutrition 0.000 claims description 3
- 229920005615 natural polymer Polymers 0.000 claims description 3
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 claims description 3
- 235000010199 sorbic acid Nutrition 0.000 claims description 3
- 239000004334 sorbic acid Substances 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims description 2
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 claims description 2
- 239000005995 Aluminium silicate Substances 0.000 claims description 2
- 241000416162 Astragalus gummifer Species 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229940105329 Carboxymethylcellulose Drugs 0.000 claims description 2
- 229940113118 Carrageenan Drugs 0.000 claims description 2
- 240000005497 Cyamopsis tetragonoloba Species 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 241000206672 Gelidium Species 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 2
- 240000007472 Leucaena leucocephala Species 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 claims description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 2
- 240000005158 Phaseolus vulgaris Species 0.000 claims description 2
- 229960000502 Poloxamer Drugs 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical class OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 claims description 2
- 229940116362 Tragacanth Drugs 0.000 claims description 2
- 229920001615 Tragacanth Polymers 0.000 claims description 2
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 claims description 2
- 206010047700 Vomiting Diseases 0.000 claims description 2
- GJCOSYZMQJWQCA-UHFFFAOYSA-N Xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 235000010419 agar Nutrition 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 239000004411 aluminium Substances 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- 229910000323 aluminium silicate Inorganic materials 0.000 claims description 2
- 235000012211 aluminium silicate Nutrition 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 239000000440 bentonite Substances 0.000 claims description 2
- 229910000278 bentonite Inorganic materials 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229920001888 polyacrylic acid Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229920001059 synthetic polymer Polymers 0.000 claims description 2
- 235000010487 tragacanth Nutrition 0.000 claims description 2
- 239000000196 tragacanth Substances 0.000 claims description 2
- NGSFWBMYFKHRBD-UHFFFAOYSA-N sodium;2-hydroxypropanoic acid Chemical compound [Na+].CC(O)C(O)=O NGSFWBMYFKHRBD-UHFFFAOYSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 8
- 238000003756 stirring Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000000796 flavoring agent Substances 0.000 description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 241000220223 Fragaria Species 0.000 description 5
- 235000016623 Fragaria vesca Nutrition 0.000 description 5
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 5
- 229940100692 Oral Suspension Drugs 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000036912 Bioavailability Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 230000035514 bioavailability Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000002458 Carcinoid Tumor Diseases 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 Chlorobutanol Drugs 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N Granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 Granisetron Drugs 0.000 description 1
- 230000035536 Oral bioavailability Effects 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000001262 anti-secretory Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 230000002902 bimodal Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000534 elicitor Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 229940006093 opthalmologic coloring agents Diagnostic Drugs 0.000 description 1
- 230000036220 oral bioavailability Effects 0.000 description 1
- 244000045947 parasites Species 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Abstract
The present invention relates to a new formulation of an enkephalinase inhibitor, such as racecadotril or dexecadotril, the process for the preparation thereof, and the use thereof in the treatment of diarrhoea.
Description
NEW FORM OF ADMINISTRATION OF ENKEPHALINASE INHIBITOR
The présent invention relates to a new formulation of an enkephalinase inhibitor, such as racecadotril or dexecadotril, the process for the préparation thereof, and the use thereof in the treatment of diarrhoea.
Racecadotril and dexecadotril are potent enkephalinase inhibitor with unique intestinal antisecretory activity. Racecadotril displays interestîng antidiarrhea activity, including in infants and children. The compound is insoluble in water and, for these young patients, it has to be administered in the form of suspensions, the latter being prepared extemporaneously from a granulated powder as described in WO 01/97801; this constitutes the commercial paediatric formulation which has already been used by millions of patients since its development.
Nevertheless, this commercial paediatric formulation displays some disadvantages. First a posology in strict proportion with the âge or weight of the children or infants, which is optimally required, cannot easily be respected when starting from a powder. The use of the powder to préparé suspensions requires multiple unity dosages, commercially presented in sachets containing different weights of racecadotril and which hâve to be used in variable number to préparé suspensions of strengths adapted to the age/weight of the young patients.
This introduces difficulties in the mode of préparation by the parents, in the remembering of the posology by the prescribing doctor and this leads to risks of errors. In addition, the price of such multiple formulations is inherently higher than that of e.g. a syrup, a form often used in paediatry. Further, the suspension made from resuspending the powder into water may require strong mixing and quick administration, to ensure that the full of the active ingrédient is administered; else, the granules of racecadotril may settle so that the full dose is not administered to the patient. Finally, a strict posology according age/weight of patients cannot be respected with the current commercial paediatric formulation.
There is therefore a need to provide aqueous suspensions of enkephalinase inhibitors such as racecadotril or dexecadotril.
However, there has been a préjudice so far to provide aqueous suspensions of racecadotril in view of its bitter taste, and its dégradation profile in aqueous media. In particular, one difficulty in preparîng stable suspensions of racecadotril is the risk of hydrolysis of this compound which bears an ester group and can be easily hydrolyzed into easily oxidizable and less active compounds
Antiemetic agents, such as 5-HT3 receptor antagoniste and in particular ondansetron and granisetron hâve been used with an enkephalinase inhibitor for the treatment of acute gastroenteritis, as disclosed in PCT/IB2005/000351. In practice, ondansetron is administered in the form of coated tablets, parentéral forms or suppositories for adults and in the form of parentéral forms or syrups for infants and children. It is therefore désirable to provide a single formulation to simultaneously adminîster both the enkephalinase inhibitor and the 5-HT3 receptor antagonist. However, an homogeneous powder mixing of two active principles with very different concentrations is generally difficult to obtain.
The présent inventors hâve now surprisingly discovered that some aqueous suspensions of an enkephalinase inhibitor such as racecadotril or dexecadotril unexpectedly may fulfil the above requirements.
The formulation of the invention comprises a stable aqueous suspension of an enkephalinase inhibitor which can be conveniently administered in varying volumes according to the âge or weights of infants or children. Furthermore, ondansetron being soluble in the water phase of the suspension, an homogeneous formulation can be easily obtained in spite of the large différence in concentrations of the two active principles.
The stable aqueous suspensions of the invention are made possible in particular by carefully adjusting the pH of the suspension. The aqueous suspensions of the invention unexpectedly show stability, improved oral bioavailability over the known suspension made up from the powder, and lack of toxicity in rodents.
According to a first object, the présent invention thus concerne an aqueous suspension of an enkephalinase inhibitor suitable for oral administration, wherein said suspension has a pH comprised between 3.5 and 5.
Said enkephalinase inhibitor may be racecadotril or dexecadotril.
Said pH is preferably comprised between 4 and 4.5, more preferably between 4 and 4.2, still more particularly about 4.
Said pH may be achieved by the presence of suitable buffering agents able to adjust the pH of the aqueous suspension within the desired pH range, in particular sodium citrate, lactic acid including diluted lactic acid (e.g. 5% lactic acid) and/or their mixtures.
Said buffering agent is generally présent in sufficient concentration so as to achieve the desired pH.
Said suspension generally comprises at least one thickening agent and/or suspending agent(s), preferably at least one thickening agent.
Said thickening agents may be chosen from cellulose and its dérivatives such as hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, ethylcellulose, 5 hydroxypropylmethylcellulose, carboxymethyl-cellulose, microcrystalline cellulose blends;
synthetic polymers such as crosslinked polyacrylate, polyvinylpyrrolidone, polyvinyl alcohol, poloxamer and carbomers.
Said suspending agents may be chosen from sucrose; or other natural polymers such as alginates, gums including xanthan, guar, agar-agar, bean locust, acacia, tragacanth, 10 carrageenan; clays such as magnésium aluminium silicate, aluminium metahydroxyde, bentonite, magnésium hectorite; ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters.
Preferably, the suspension of the invention comprises at least one cellulose dérivative and at least one natural polymer; preferably hydroxyethylcellulose and xanthan gum.
The aqueous suspension of the invention may additionally comprise one component selected from the group comprising pharmaceutically acceptable carriers, diluents, adjuvants, excipients, or vehicles, such as preservatives, fillers, disintegrating agents, wetting agents, emulsifying agents, sweetening agents, flavoring agents, colouring agents, perfuming agents, antibacterial agents, antifungal agents.
Prévention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phénol, sorbic acid, and the like.
Examples of suitable carriers, diluents, solvents or vehicles in addition to water include éthanol, polyols, suitable mixtures thereof, vegetable oils (such as olive oil).
Generally, the aqueous suspension of the invention comprises at least one preservative, in particular chosen from sodium benzoate, benzoic acid, sorbic acid and their salts, more preferably sodium benzoate.
Generally, the aqueous suspension of the invention comprises at least one sweetening 30 agent such as sucrose.
Generally, the aqueous suspension of the invention comprises at least one flavouring agent such as artificial flavours.
The présent invention further encompasses aqueous suspension as defined above additionally comprising ondansetron
A typical aqueous suspension of the invention may comprise:
at least one enkephalinase inhibitor: 2 to 5 g/l of suspension, preferably about 4g/l;
- at least one thickening and/or suspending agent(s), preferably at least one thickening agent: 4 to 16 g/l of suspension;
- buffering agent so as to adjust to the desired pH.
It may additionally comprise one of the following ingrédients: preservative: 1 to 6 g/l of suspension; and/or sweetening agent: 550 to 650 g/l of suspension; and/or
- flavouring agent : 0,8 to 5, preferably 0,8 to 1,2 g/l of suspension.
Particular aqueous suspensions of the invention may further comprise :
- ondansetron: 0,1 to 0,8 g/l of suspension, preferably 0.05 to 0.5, more preferably about 0,4 g/l.
The compositions can be prepared by any of the methods well known in the art of pharmacy. Such methods comprise mixing together the ingrédients of the aqueous suspension and include the step of bringing into association the active ingrédient with the carrier which constitutes one or more accessory ingrédients. In general the compositions are prepared by uniformly and întimately bringing into association the active ingrédient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
The process of the invention comprises the step of adding a buffering agent to an aqueous suspension of an enkephalinase inhibitor so as to adjust the pH between 3.5 and
5.
The process of préparation may further comprise the preliminary steps of:
- optionally adding the optional sweetening agent and/or preservative to water;
- dispersing the enkephalinase inhibitor and at least one thickening and/or suspending agent(s) and the optional ondansetron, flavouring agent(s) and/or preservative(s) in water which may contain the optional sweetening agent.
Altematively, the process of préparation may further comprise the preliminary steps of:
- dispersing the enkephalinase inhibitor with optional sweetening agent(s), flavouring agent(s), preservative(s) and/or ondansetron in water, and
- adding at least one thickening and/or suspending agent(s). prf
The dispersion may be stirred to obtain a final suspension.
The pH may be adjusted by mixing a first buffering agent with the enkephalinase inhibitor dispersion and then adding a second buffering agent to the final suspension.
Said dispersing is generally conducted under stirring, at a température comprised between room température and 70°C.
Preferably, said dispersing step is conducted following the step of dissolving any preservative into water.
The process may further comprise the additional step of homogenizing the size of the suspended particles by grinding the suspension.
According to another preferred aspect, the aqueous suspension of the invention allows the précisé administration of 1.5 mg/kg of body weight which allows the administration of a dose of less that 6 mg for children or babies.
Generally, 2.5 ml of the aqueous suspension delivers the same dose (10 mg) of racecadotril as the commercially available sachet of coated granules of racecadotril.
According to another preferred aspect, the aqueous suspension of the invention allows the administration of 1 and 8 mg, preferably between 2 to 8 mg of ondansetron per dosage unit for adults of 0.2 to 4 mg for children or babies.
Generally, 2.5 ml of the aqueous suspension delivers from 0.25 mg to 2 mg of ondansetron, preferably about 0.5 mg of ondansetron.
In accordance with another subject-matter, the présent invention also relates to aqueous suspensions of enkephalinase inhibitor for use for the treatment and/or prévention of diarrhoea, and/or acute gastroenteritis.
According to a preferred aspect, when the aqueous suspension further comprises ondansetron, the invention also concems said aqueous suspension for use for the treatment and/or prévention of acute diarrhoea associated with emesis.
According to a still preferred aspect, said diarhoea is chemotherapy- induced diarrhoea, carcinoid diarrhoea, travelleris diarrhoea, diarrhoea elicited by various bacteria, viruses or parasites in adults, children or babies. riT
According to another preferred aspect, said treatment comprises oral administration, preferably two to four times a day.
Figure 1 illustrâtes the pharmacokinetic profile of the biologically active moiety of racecadotril after oral administration of the aqueous suspension of racecadotril (48 mg/kg) in Swiss male mice (n=4).
Figure 2 illustrâtes the stability ofthe aqueous suspension of racecadotril (10 mg/2.5 mL) and shows the effect of the pH of the aqueous suspension of racecadotril on the concentration of a dégradation product of racecadotril (benzylthiorphandisulfure).
Figure 3 illustrâtes the stability of the aqueous suspension of racecadotril and ondansetron (10mg/1 mg/2.5 mL) and shows the effect of the pH of the aqueous suspension of racecadotril/ondansetron on the concentration of a dégradation product of racecadotril (benzylthiorphandisulfure) appearing upon storage.
The following examples are provided as a non-limiting illustration ofthe présent invention.
Example 1 : Préparation of an aqueous suspension of racecadotril
As per 500 mL of oral suspension:
In 175 mL of purified water, 2.500 g of sodium benzoate were slowly added under stirring until complété dissolution. The solution was heated to about 60°C under continuous stirring and 300.000 g sucrose were added. While continuing stirring slowly, the solution was then cooled down to about 30°C and the following materials were slowly added under high-speed dispersion:
Racecadotril 2.000g
Xanthan gum 2.500g
Hydroxyethylcellulose 2.500g
Strawberry flavor 0.500g
Slow stirring was maintained for about 30 minutes, and then under slow mixing 3.750 g of sodium citrate were added. Slow stirring was continued for about 20 minutes. The pH of the so obtained suspension was then adjusted to 4.0 with a lactic acid solution 5 % m/v.
The final volume (500 mL) of the suspension was adjusted while continuing slowly stirring with purified water.
Constituent | Quantity (unit formula) | Quantity (as per 100 ml of oral suspension) | Fonction |
Racecadotril | 0.16000 g | 0.4000 g | Active ingrédient |
Excipients : | |||
Sodium benzoate | 0.20000 g | 0.5000 g | Preservative |
Hydroxyethylcellulose | 0.20000 g | 0.5000 g | Thickening agent |
Xanthan gum | 0.20000 g | 0.5000 g | Suspending agent |
Strawberry flavour | 0.04000 g | 0.1000 g | Flavoring agent |
Sucrose | 1.50000 g | 60.0000 g | Sweetening and suspending agent |
Sodium citrate | 0.30000 g | 0.7500 g | Buffering agent |
Lactic acid | QS pH 4,0 ± 0.2 | QS pH 4,0 ± 0.2 | Buffering agent |
Purified water | QS 40 mL | QS 100 mL | Solvent |
Example 2a : Aqueous suspension of racecadotril/ondansetron
As per 500 mL of oral suspension:
In 175 mL of purified water, 2.500g of sodium benzoate were slowly added under stirring until complété dissolution. The solution was heated to about 60°C under continuous stirring and 300.000 g sucrose were added. While continuing stirring slowly, the solution was then cooled down to about 30°C and the following materials were slowly added under high-speed dispersion:
Racecadotril | 2.000 g |
Ondansetron | 0.100 g |
Xanthan gum | 2.500 g |
Hydroxyethylcellulose | 2.500 g |
Strawberry flavor | 0.500 g |
Slow stirring was maintained for about 30 minutes, and then under slow mixing 3.750 g of sodium citrate were added. Slow stirring was continued for about 20 minutes. The pH of the so obtained suspension was then adjusted to 4.0 with a lactic acid solution 5 % m/v.
The final volume (500 mL) of the suspension was adjusted while continuing slowly stirring with purified water.
Constituent | Quantity (unit formula) | Quantity (as per 100 ml of oral suspension) | Fonction |
Racecadotril | 0.16000 g | 0.4000 g | Active ingrédient |
Ondansetron | 0,008000 | 0.0200 g | Active ingrédient |
Excipients : | |||
Sodium benzoate | 0.20000 g | 0.5000 g | Preservative |
Hydroxyethylcellulose | 0.20000 g | 0.5000 g | Thickening agent |
Xanthan gum | 0.20000 g | 0.5000 g | Suspending agent |
Strawberry flavour | 0.04000 g | 0.1000 g | Flavoring agent |
Sucrose | 1.50000 g | 60.0000 g | Sweetening and suspending agent |
Sodium citrate | 0.30000 g | 0.7500 g | Buffering agent |
Lactic acid | QS pH 4,0 ± 0.2 | QS pH 4,0 ± 0.2 | Buffering agent |
Purified water | QS 40 mL | QS 100 mL | Solvent |
Example 2b : Aqueous suspension of racecadotril/ondansetron
As per 2 500 L of oral suspension
In about 315 L of purified water, 1 500 kg of sucrose in solution at about % were added under stirring. Under continuous stirring introduce until complété dissolution/dispersion:
- Sodium benzoate 7.50 kg
- Ondansetron 0.5 kg
-Racecadotril 10 kg
- Hydroxethylcellulose 12.50 kg
-Xanthangum 12.50 kg
- Sodium citrate 18.75 kg
- Strawberry flavor 7.70 kg
Then, under stirring, adjust the pH of the so obtained suspension within 4.0 to 4.2 with a lactic acid solution 60 % m/v.
Adjust final volume (2 500 L) of the suspension with purified water while continuing stirring.
Homogenize size of particles suspended by continuous grinding of the suspension for 8 hours, then heat the suspension to a température of 40°C under slow stirring and under vacuum to allow air bubbles to migrate out of the suspension.
Example 3 : Pharmacokînetic profile
Racecadotril was orally administered (48mg/kg) to 24 mice (n=4 per value) in the form of powder resuspended in water and in the form of the aqueous suspension of example 1, The concentration of the active moiety of racecadotril (DT326) in plasma is measured. Results are illustrated in Figure 1. They show that the bioavailability of racecadotril when administered in the aqueous suspension is increased by 50% in comparison of that when administered in the form of powder resuspended in water.^'
Example 4 : Stabilîty
The pH of the suspensions of example 1 (10 mg racecadotril ! 2,5mL) and 2 (10 mg racecadotril /1 mg ondansetron / 2, 5 ml) was adjusted to 4, 4.5 and 5. The three samples for each suspension were stored under the following accelerated conditions at 40°C / 75% relative humidity during 6 weeks.
Following the storage, the % of a dégradation product of racecadotril (benzylthiorphandisulfure) was measured for each value of the pH. Results are illustrated in Figures 2 and 3. They show that the dégradation unexpectedly decreases as the pH decrease, as hydrolysis generally increases in acidic conditions. In view of these results and the racecadotril spécification, an optimal range of pH comprised between 3.5 and 5 may be considered.
Example 5 : Particle size distribution profile of the suspension
Particle size distribution profile of racecadotril in suspension obtained in example 2b was determined using laser diffraction measurement and shows a bimodal distribution corresponding to 50 % of particles in volume within 1 pm to about 70 pm with the upper limit of about 750 pm. This profile is advantageous in that the suspension exhibit both improved bioavailability (with the smaller particles) and stabilîty (with the larger particles).^
Claims (15)
1. An aqueous suspension of an enkephalinase inhibitor suitable for oral administration, wherein said suspension has a pH comprised between 3.5 and 5, wherein said enkephalinase inhibitor is racecadotril or dexecadotril.
2. The aqueous suspension according to claim, wherein said pH is comprised between 4 and 4.5.
3. The aqueous suspension according to anyone of the preceding daims further comprising one or more buffering agent(s).
4. The aqueous suspension according to claim 3, wherein said buffering agent is chosen from sodium citrate, lactic acid and their mixtures.
5. The aqueous suspension according to anyone of the preceding daims further comprising one or more thickening and/or suspending agent(s).
6. The aqueous suspension according to daim 5, wherein said thickening and/or suspending agent is (are) chosen from the group consisting in cellulose and its dérivatives such as hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, carboxymethyl-cellulose, microcrystalline cellulose blends; synthetic polymers such as crosslinked poiyacrylate, polyvinylpyrrolidone, polyvinyl alcohol, poloxamer and carbomers; sucrose; or other natural polymers such as alginates, gums including xanthan, guar, agar-agar, bean locust, acacia, tragacanth, carrageenan; clays such as magnésium aluminium silicate, aluminium metahydroxyde, bentonite, magnésium hedorite; ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters; and the mixtures thereof.
7. The aqueous suspension according to claim 6, wherein said thickening and/or suspending agent(s) are chosen from hydroxyethylcellulose, xanthan gum, and the mixtures thereof.
8. The aqueous suspension according to anyone of the preceding daims further comprising at least one preservative. hT
9. The aqueous suspension according to claim 8 wherein said preservative is chosen from sodium benzoate, benzoic acid, sorbic acid and their salts, more preferably sodium benzoate.
5
10. The aqueous suspension according to anyone of the preceding daims further comprising at least one sweetening agent and/or flavourîng agent.
11. The aqueous suspension according to anyone of the preceding daims further comprising ondansetron.
12. The aqueous suspension according to anyone of the preceding daims comprising:
- at least one enkephalinase inhibitor: 2 to 5 g/l of suspension,;
- at least one thickening and/or suspending agent(s): 4 to 16 g/l of suspension;
- buffering agent so as to adjust to the desired pH.
13. The aqueous suspension according to anyone of the preceding daims further comprising one or more of the following ingrédients:
- preservative: 1 to 6 g/l of suspension; and/or
- sweetening agent: 550 to 650 g/l of suspension; and/or
20 - flavourîng agent : 0,8 to 5 g/l of suspension.
14. The aqueous suspension according to anyone of the preceding daims further comprising:
- ondansetron: 0,1 to 0,5 g/l of suspension.
15. The process of préparation of an aqueous suspension according to anyone of the preceding daims comprising the step of adding a buffering agent to an aqueous suspension of said enkephalinase inhibitor so as to adjust the pH between 3.5 and 5.
30 16. An aqueous suspension of said enkephalinase inhibitor according to anyone of the preceding daims for use for the treatment and/or prévention of diarrhoea, acute gastroenteritis, and/or acute diarrhoea associated with emesis.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10306397.0 | 2010-12-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA16449A true OA16449A (en) | 2015-10-15 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2820835C (en) | New form of administration of enkephalinase inhibitor | |
EP2214637A1 (en) | Stabilized pediatric suspension of carisbamate | |
US11730732B2 (en) | Oral suspension of temozolomide | |
US10596263B2 (en) | Pazopanib formulation | |
AU2004257556C1 (en) | A stable clozapine suspension formulation | |
OA16449A (en) | New form of administration of enkephalinase inhibitor. | |
CN101972230A (en) | Pirfenidone for suspension and preparation method | |
US11890273B2 (en) | Losartan liquid formulations and methods of use | |
WO2020212898A1 (en) | Pharmaceutical oral liquid solution of ivacaftor | |
WO2013062497A1 (en) | Liquid pharmaceutical formulations |